Beijing Tiantan Hospital, Capital Medical University
Beijing, Beijing Municipality, 100070, China
Location status: Recruiting
NCT Number: NCT06224426
The goal of this clinical trial is to compare the effects of different concentrations of normobaric oxygen on early neurological improvement in acute ischemic stroke (AIS) patients receiving endovascular therapy (EVT). The main questions it aims to answer are:
* Evaluating the impact of normobaric high-concentration oxygen versus low-concentration oxygen on early neurological function after EVT. * Evaluating the safety of high and low normobaric oxygen concentration in patients with ischemic stroke.
Participants will (1) receive EVT under general anesthesia; (2) be randomly assigned 1:1 to receive oxygen therapy with FiO2=80% or FiO2=30% through endotracheal intubation during the operation, and the gas flow rate was set at 4L /min.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Beijing, Beijing Municipality, 100070, China
Location status: Recruiting
The optimal fraction of inspired oxygen (FiO2) during EVT under general anesthesia is currently uncertain. This is a randomized controlled trial (RCT) designed to assess the impact of normobaric high-concentration oxygen versus low-concentration oxygen on early neurological function following EVT. It is a prospective, open-label, parallel-design RCT planned to be conducted at Beijing Tiantan Hospital, Capital Medical University. It is anticipated that 200 cases of AIS patients undergoing EVT under general anesthesia will be consecutively enrolled from 2024 to 2026. Eligible participants will be randomly assigned in a 1:1 ratio. After general anesthesia induction, patients will receive continuous inhalation of oxygen with either FiO2=80% or FiO2=30% through endotracheal intubation until the end of the procedure, with a gas flow rate set at 4 L/min. The positive end-expiratory pressure (PEEP) is uniformly set to 5 cmH2O to balance its effect on pulmonary oxygen delivery. The primary outcome will be the occurrence of early neurological improvement (NIHSS score of 10 points 24±2 hours after EVT). Safety outcomes include potential adverse events such as site infection, three-month mortality, etc.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
During endovascular therapy, eligible participants will receive FiO2=80% through endotracheal intubation, with a gas flow rate set at 4 L/min.
During endovascular therapy, eligible participants will receive FiO2=30% through endotracheal intubation, with a gas flow rate set at 4 L/min.
Time frame: 24±2 hours after EVT
ENI is defined as an NIHSS score of <10 points at 24±2 hours after EVT
Time frame: 24±2 hours after EVT
baseline NIHSS score - NIHSS score at 24±2 h
Time frame: 72 hours post-randomization
After collecting cranial CT images, the infarct volume was delineated using ITK-SNAP software.
Time frame: 1 day after reperfusion therapy
an increase of ≥4 from the baseline NIHSS score on day 1 after reperfusion therapy in AIS patients
Time frame: within 7 days after endovascular therapy
defined as a composite measure encompassing pulmonary infections, atelectasis, pleural effusion, respiratory failure, bronchospasm, and pneumothorax
Time frame: 90 days after stroke onset
modified Rankin scale (mRS) scores are distributed between 0 and 6
Time frame: 90 days after stroke onset
an mRS score of 0-2 at 90 days
Time frame: From the end of the intervention procedure until the time just before the tracheal tube is removed.
Arterial partial oxygen pressure based on arterial blood gas
Time frame: From the end of the intervention procedure until the time just before the tracheal tube is removed.
oxygenation index=PaCO2/FiO2
Time frame: 24±12 hours after EVT
defined as the presence of hemorrhage on CT at 24±12 h accompanied by an NIHSS score increase≥4
Time frame: 90 days after stroke onset
deaths from any cause during the 3-month follow-up period
Time frame: within 7 days after endovascular therapy
typically defined as death directly attributable to the stroke and its complications, encompassing but not limited to severe cerebral edema, brain herniation, infections, cardiac diseases, pulmonary embolism, and deep vein thrombosis occurring during the acute phase of AIS
Contact information is provided by the study sponsor or research team.
Ruquan Han, Ph.D
CONTACT
Zhengfang Hu, M.D
CONTACT
Beijing Tiantan Hospital
Other
Oxygenation Targets for Endovascular Therapy in Acute Ischemic Stroke Patients (Oxy-TARGET)
Acronym: Oxy-TARGET
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07367100
Brain Diseases, Cardiovascular Diseases
Edegem, Belgium
View Trial DetailsNCT07345702
Basilar Artery Occlusion, Brain Diseases
Beijing, Beijing Municipality, China
View Trial DetailsNCT05032053
Brain Diseases, Cardiovascular Diseases
Ankang, Shaanxi, China
View Trial DetailsNCT07736885
Brain Diseases, Cardiovascular Diseases
Tianjin, Tianjin Municipality, China
View Trial Details